申联生物
(688098)
| 流通市值：23.41亿 | | | 总市值：23.41亿 |
| 流通股本：4.11亿 | | | 总股本：4.11亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 96,483,629.97 | 146,206,489.54 | 105,113,241.13 | 138,282,087.67 |
| 应收票据及应收账款 | 303,259,258.69 | 261,397,654.93 | 315,111,042.23 | 272,296,695.34 |
| 其中：应收票据 | 1,099,939.5 | 0 | - | - |
| 应收账款 | 302,159,319.19 | 261,397,654.93 | 315,111,042.23 | 272,296,695.34 |
| 预付款项 | 895,412.95 | 1,078,554.81 | 1,174,527.45 | 1,174,854.8 |
| 其他应收款合计 | 3,407,026.69 | 3,170,654.55 | 3,575,043.05 | 3,841,461.41 |
| 存货 | 93,127,951.11 | 95,102,892.07 | 95,054,545.33 | 114,204,357.32 |
| 其他流动资产 | 59,659.39 | 59,659.39 | 59,659.39 | 56,515.38 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 541,938,797.03 | 550,830,796.15 | 581,043,452.61 | 570,361,006.28 |
| 非流动资产: | | | | |
| 长期股权投资 | 11,588,127.57 | 1,582,608.87 | 3,587,465.88 | 1,583,061.78 |
| 其他权益工具投资 | 5,000,000 | 5,000,000 | - | - |
| 固定资产 | 749,600,517.5 | 631,281,073.17 | 638,076,048.22 | 651,514,304.45 |
| 在建工程 | 58,996,253.29 | 177,870,534.68 | 166,643,230.59 | 156,524,507.97 |
| 生产性生物资产 | 233,795.46 | 312,807.95 | 139,356.39 | 156,973.02 |
| 使用权资产 | 2,313,921.75 | 1,726,628.01 | 1,960,002.71 | 2,288,276.95 |
| 无形资产 | 100,323,925.4 | 102,664,230.95 | 104,970,938.58 | 107,169,376.83 |
| 开发支出 | 36,944,445.18 | 33,184,095.1 | 49,895,290.31 | 45,863,682.47 |
| 递延所得税资产 | 13,494,919.63 | 13,259,954.26 | 7,265,174.39 | 5,736,367.36 |
| 其他非流动资产 | 40,225,641.1 | 36,405,220 | 28,430,450 | 15,975,365.69 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 1,018,721,546.88 | 1,003,287,152.99 | 1,000,967,957.07 | 986,811,916.52 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 1,560,660,343.91 | 1,554,117,949.14 | 1,582,011,409.68 | 1,557,172,922.8 |
| 流动负债: | | | | |
| 短期借款 | 14,008,341.66 | 14,008,341.67 | - | - |
| 应付票据及应付账款 | 9,111,752.12 | 5,438,414.72 | 8,272,822.39 | 3,504,296.51 |
| 应付账款 | 9,111,752.12 | 5,438,414.72 | 8,272,822.39 | 3,504,296.51 |
| 合同负债 | 17,301,686.21 | 17,343,332.38 | 12,294,209.51 | 18,536,073.78 |
| 应付职工薪酬 | 6,586,454.57 | 15,225,900.61 | 13,664,396.02 | 9,323,464.54 |
| 应交税费 | 3,628,702.74 | 1,598,708 | 2,868,884.76 | 1,130,010.67 |
| 其他应付款合计 | 67,110,625.83 | 52,591,117.74 | 45,766,028.09 | 44,619,299.5 |
| 应付股利 | 553,005.07 | 553,005.07 | 553,005.07 | 1,879,743.4 |
| 一年内到期的非流动负债 | 598,918.47 | 475,512 | 520,132.8 | 563,038.28 |
| 其他流动负债 | 10,054,162.99 | 9,520,015.15 | 11,218,239.96 | 10,782,149.16 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 128,400,644.59 | 116,201,342.27 | 94,604,713.53 | 88,458,332.44 |
| 非流动负债: | | | | |
| 租赁负债 | 1,438,411.22 | 1,005,937.22 | 1,226,859.56 | 1,630,223.77 |
| 递延收益 | 10,587,704.85 | 11,080,949.34 | 10,431,336.79 | 10,810,295.56 |
| 递延所得税负债 | 345,615.35 | 207,258.25 | 73,508.46 | 14,252.24 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 12,371,731.42 | 12,294,144.81 | 11,731,704.81 | 12,454,771.57 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 140,772,376.01 | 128,495,487.08 | 106,336,418.34 | 100,913,104.01 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 410,644,000 | 410,644,000 | 410,644,000 | 410,644,000 |
| 资本公积 | 539,233,471.91 | 539,233,471.91 | 539,233,471.91 | 539,233,471.91 |
| 减:库存股 | 20,004,297.06 | 18,324,408.37 | - | - |
| 盈余公积 | 75,020,487.07 | 75,020,487.07 | 75,020,487.07 | 75,020,487.07 |
| 未分配利润 | 401,701,795.55 | 404,721,662.16 | 435,337,038.97 | 414,953,747.05 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 1,406,595,457.47 | 1,411,295,212.77 | 1,460,234,997.95 | 1,439,851,706.03 |
| 少数股东权益 | 13,292,510.43 | 14,327,249.29 | 15,439,993.39 | 16,408,112.76 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 1,419,887,967.9 | 1,425,622,462.06 | 1,475,674,991.34 | 1,456,259,818.79 |
| 负债和股东权益合计 | 1,560,660,343.91 | 1,554,117,949.14 | 1,582,011,409.68 | 1,557,172,922.8 |
| 公告日期 | 2025-04-30 | 2025-04-30 | 2024-10-31 | 2024-08-30 |
| 审计意见(境内) | | 标准无保留意见 | | |